Global Human Platelet Lysate Market Report and Forecast 2025-2034

Global Human Platelet Lysate Market Outlook

The global human platelet lysate market size was valued at USD 52.53 million in 2023. The market is being driven by the rising incidences of various health-related issues and increasing investments in R&D activities of stem cell therapy. The market is anticipated to grow at a CAGR of 3.6% during the forecast period 2024-2032 to reach a value of USD 72.21 million by 2032.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Growing Incidences of Health-Related Issues Augmenting the Market Growth of Human Platelet Lysate

The growth of the human platelet lysate or hPL market is being driven by the growing incidences of chronic autoimmune diseases, haematological and neurological disorders, and cardiovascular and infectious diseases, among others. This, in turn, is increasing the applications of progenitor and stem cell-based therapies, hence surging the demand. With the increasing focus on quality issues regarding purity, traceability, potency, safety, and identity of hPLs, the market is poised to witness lucrative growth opportunities in the coming years.

North America Accounts for a Significant Share of the Market for Human Platelet Lysate

North America holds a significant share of the market, which can be attributed to their extensive utilisation of hPL as a substitute for fetal bovine serum in various applications. Surging investments in research and development (R&D) activities of stem cell therapy by leading companies and governments are bolstering the growth of the market. For instance, in March 2020, the Canadian government announced an investment of about USD 7 million in regenerative medicine and stem cell research.

Meanwhile, Europe is anticipated to be one of the fastest-growing regional markets. This can be associated with the rising use of hPL in manufacturing cell therapeutics due to ethical issues pertaining to animal-derived raw materials in the region.

Market Segmentation

Human platelet lysate or hPL refers to a cell culture supplement that is typically used as an alternative to fetal bovine serum (FBS) for human cell propagation and culture. It is manufactured from intermediate side products of whole blood donations and is rich in growth factors and chemokine molecules. In addition, the product is used to grow mesenchymal stem cells that are derived from diverse species like rabbits and humans, among others.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on major types, the market is divided into:

• Heparin-based Human Platelet Lysate

• Heparin-free Human Platelet Lysate

• Others

The market can be broadly categorised on the basis of its end uses into:

• Pharmaceutical and Biotechnology Companies

• Academic and Research Institutes

• Others

By application, the market is segmented into:

• Research

• Therapeutic

The EMR report looks into the regional markets of human platelet lysate like North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Increasing Interest in Cell-Based Therapies to Fuel the Market Growth of Human Platelet Lysate

The growing interest in cell-based therapies such as mesenchymal stem cell-based therapy is leading to a surge in demand. As growth supplements like foetal bovine serum (FBS) are xenogeneic products and can induce immunologic reactions, hPL is deployed as their alternative.

Advancements in pathogen reduction technologies to boost the safety of hPL are also likely to fuel the market growth. The increasing research and development (R&D) activities to identify the potential of the cell culture growth supplement in the production of clinical-grade cell therapy products are anticipated to provide impetus to market growth.

Due to the growing ethical and animal welfare concerns in the medical and pharmaceutical sectors, hPL is increasingly preferred as it can be produced from outdated platelets. Its surging use for research-grade expansion of endothelial colony-forming progenitor cells is also expected to significantly contribute to the growth of the market. With increasing clinical trials and research activities, the demand for the product in human cell expansion is rising, propelling the growth of the market in the coming years.

Key Players in the Global Human Platelet Lysate Market

The report presents a detailed analysis of the following key players in the global human platelet lysate market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

• Merck KGaA

• Compass Biomedical, Inc.

• STEMCELL Technologies Inc.

• Sartorius AG

• Life Science Group Ltd

The comprehensive report looks into the macro and micro aspects of the market. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

Key Highlights of the Report